Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: A randomized controlled trial with losartan

Circulation

Volumn 103, Issue 2, 2001, Pages 226-230

  Myerson, Saul G ^a   Montgomery, Hugh E ^a   Whittingham, Martin ^b   Jubb, Mick ^b   World, Michael J ^b   Humphries, Steve E ^a   Pennell, Dudley J ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Royal Defence Medical College   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Angiotensin; Exercise; Genetics; Hypertrophy; Myocardium

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; LOSARTAN;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; EXERCISE; GENE DELETION; GENE INSERTION; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035895320     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.2.226     Document Type: Article

References (43)

1. Role of the cardiac renin-angiotensin system in hypertensive cardiac hypertrophy
2. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: Effects on coronary resistance, contractility, and relaxation
3. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
4. An insertion/deletion polymorphism in the angiotensin-1-converting enzyme gene accounting for half the variance of serum enzyme levels
5. Angiotensin converting enzyme in the human heart: Effect of the deletion/insertion polymorphism
6. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training
7. Angiotensin II and left ventricular growth in newborn pig heart
8. Angiotensin II stimulation in vitro induces hypertrophy of normal postinfarcted ventricular myocytes
9. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril
10. Human gene for physical performance
11. Normal human right and left ventricular mass, systolic function gender differences by cine magnetic resonance imaging
12. Quantification of adipose tissue by MRI: Relationship with anthropometric variables
13. Unbiased estimation of human body composition by the Cavalieri method using magnetic resonance imaging
14. The associations of body size and body composition with left ventricular mass: Impacts for indexation in adults
15. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans
16. Dose-response relationships following oral administration of DuP 753 to normal humans
17. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers, inhibition of pressor response to exogenous angiotensin I and II
18. Clinical experience with angiotensin II receptor antagonists
19. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects
20. The clinical pharmacology of losartan in Japanese subjects and patients
21. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men
22. Blood pressure effects of the angiotensin II receptor blocker, losartan
23. Inhibitors of the renin-angiotensin system: Clinical pharmacology studies on kinetics, dynamics concentration-effect relationships
24. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man
25. Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans
26. Effects of losartan on blood pressure, plasma renin activity and angiotensin II in volunteers
27. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted nonnotensives
28. Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle
29. 1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats
30. 1 receptor
31. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases
32. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis
33. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method
34. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
35. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
36. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient
37. Should echocardiography be performed to assess effects of antihypertensive therapy?: Test-retest reliability of echocardiography for measurement of left ventricular mass and function
38. Cardiovascular adaptations to chronic exercise
39. Structural features of the athlete's heart as defined by echocardiography
40. Physiological left ventricular hypertrophy
41. Isometric exercise and the cardiovascular system
42. Should the contribution of ACE gene polymorphism to left ventricular hypertrophy be reconsidered?
43. Insertion/deletion polymorphism in the angiotensin-converting-enzyme gene and blood pressure during ergometry in normal males